Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Revenue projections:

Revenue projections for ASTRAZEN
Revenue projections for ASTRAZEN



Financial Ratios:

currentRatio 1.90900
forwardPE 0.00000
debtToEquity 4.63800
earningsGrowth 0.47600
revenueGrowth 0.25400
grossMargins 0.43890
operatingMargins 0.14294
trailingEps 46.55000
forwardEps 0.00000

ASTRAZEN's current ratio being 1.909 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, ASTRAZEN can easily cover its immediate liabilities, reflecting solid financial health.
AstraZeneca Pharma India Limited's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that AstraZeneca Pharma India Limited is expected to continue expanding its business and boosting its financial performance in the coming periods.